Next Article in Journal
Medico-Economic Study of Pain in an Emergency Department: A Targeted Literature Review
Previous Article in Journal
Systematic Review of Utility Values Used in the Pharmacoeconomic Evaluations for Schizophrenia: Implications on Cost-Effectiveness Results
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 7
Issue 1
10.1080/20016689.2019.1650596
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Why "American Patients First" Is Likely to Raise Drug Prices outside of the United States

by
Monique Dabbous
1,*,
Cyprien Milea
2,
Steven Simoens
3,
Clement François
1,
Claude Dussart
4,
Lylia Chachoua
5,
Borislav Borissov
6 and
Mondher Toumi
1
1
Public Health Department, Aix-Marseille University, Marseille, France
2
International Affairs, Sciences Po, Paris, France
3
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
4
EA 4129 P2S (Parcours, Santé, Systémique), Lyon University, Lyon, France
5
Public Health Department, Market Access Society, Paris, France
6
Prescriptia, Sofia, Bulgaria
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1650596; https://doi.org/10.1080/20016689.2019.1650596
Submission received: 19 April 2019 / Revised: 23 July 2019 / Accepted: 26 July 2019 / Published: 9 August 2019

Abstract

Background: The Trump administration’s ‘American Patients First’ blueprint proposes to reduce drug prices in the USA by increasing drug prices abroad, ex USA. The possibility of the Trump administration to raise drug prices ex USA through legal action via the WTO and bilateral negotiations with foreign trade partners was reviewed. Methods: A literature review was conducted through PUBMED, EMBASE, Media and grey literature to consolidate publications of the Trump administrations’ policies and strategies towards foreign countries and drug prices. Results: The Trump administration has withdrawn from and halted major multilateral agreements including the TPP, Paris Agreement, TTIP, UNESCO, NAFTA (now USMCA), and NATO. The Trump administration has been successful in bilateral negotiations for pharmaceuticals’ pricing, as seen with Japan, South Korea, Germany, and Mexico and Canada. Conclusion: The objective of raising prices abroad is attainable. Action through the WTO is unlikely, due to its nondiscriminatory principle. Bilateral trade negotiation have proven more promising. In this bilateral framework, financial security and military protection are strong assets for the USA to levy higher drug prices abroad. Although raising drug prices ex USA is possible, further questions as to whether this will directly translate into lower drug prices for American patients are raised.
Keywords: drug prices; United States of America (USA); Trump; American Patients First (APF); free-loading; bilateralism; multilateralism; World Trade Organization (WTO); foreign policy drug prices; United States of America (USA); Trump; American Patients First (APF); free-loading; bilateralism; multilateralism; World Trade Organization (WTO); foreign policy

Share and Cite

MDPI and ACS Style

Dabbous, M.; Milea, C.; Simoens, S.; François, C.; Dussart, C.; Chachoua, L.; Borissov, B.; Toumi, M. Why "American Patients First" Is Likely to Raise Drug Prices outside of the United States. J. Mark. Access Health Policy 2019, 7, 1650596. https://doi.org/10.1080/20016689.2019.1650596

AMA Style

Dabbous M, Milea C, Simoens S, François C, Dussart C, Chachoua L, Borissov B, Toumi M. Why "American Patients First" Is Likely to Raise Drug Prices outside of the United States. Journal of Market Access & Health Policy. 2019; 7(1):1650596. https://doi.org/10.1080/20016689.2019.1650596

Chicago/Turabian Style

Dabbous, Monique, Cyprien Milea, Steven Simoens, Clement François, Claude Dussart, Lylia Chachoua, Borislav Borissov, and Mondher Toumi. 2019. "Why "American Patients First" Is Likely to Raise Drug Prices outside of the United States" Journal of Market Access & Health Policy 7, no. 1: 1650596. https://doi.org/10.1080/20016689.2019.1650596

APA Style

Dabbous, M., Milea, C., Simoens, S., François, C., Dussart, C., Chachoua, L., Borissov, B., & Toumi, M. (2019). Why "American Patients First" Is Likely to Raise Drug Prices outside of the United States. Journal of Market Access & Health Policy, 7(1), 1650596. https://doi.org/10.1080/20016689.2019.1650596

Article Metrics

Back to TopTop